MAPK3 and lung cancer: In lung cancer, KDM2A was reported to be a novel oncogenic promoter of non-small cell lung cancer (NSCLC), and the overexpression of KDM2A was shown to promote tumorigenicity and metastasis by epigenetically enhancing ERK1/2 signaling in NSCLC [40].